NEK2 and cancer: The newly developed compound preserved the previously observed mechanism of action towards Hec1 and Nek2 and sensitized a wide array of cancer cells including several multidrug-resistant cell lines, such as MES-SA/Dx5, NCI-ADR-RES, and K562R.